Emerging Gene-Editing Modalities for Osteoarthritis

Alekya S. Tanikella  
*Boise State University*

Makenna J. Hardy  
*Boise State University*

Stephanie M. Frahs  
*Boise State University*

Aidan G. Cormier  
*Boise State University*

Kalin D. Gibbons  
*Boise State University*

*See next page for additional authors*
Emerging Gene-Editing Modalities for Osteoarthritis

Alekya S. Tanikella 1, Makenna J. Hardy 1,2,3, Stephanie M. Frahs 1,2,3, Aidan G. Cormier 4, Kalin D. Gibbons 4, Clare K. Fitzpatrick 4 and Julia Thom Oxford 1,2,3,*

1 Biomolecular Research Center, Boise State University, Boise, ID 83725, USA; atlearning2014@gmail.com (A.S.T.); makennahardy@u.boisestate.edu (M.J.H.); StephanieTuft@boisestate.edu (S.M.F.)
2 Department of Biological Sciences, Boise State University, Boise, ID 83725, USA
3 Biomolecular Sciences Graduate Programs, Boise State University, Boise, ID 83725, USA
4 Mechanical and Biomedical Engineering, Boise State University, Boise, ID 83725, USA; aidancormier@u.boisestate.edu (A.G.C.); kalingibbons@u.boisestate.edu (K.D.G.); clarefitzpatrick@boisestate.edu (C.K.F.)
* Correspondence: joxford@boisestate.edu; Tel.: +1-208-426-2395

Received: 11 July 2020; Accepted: 19 August 2020; Published: 22 August 2020

Abstract: Osteoarthritis (OA) is a pathological degenerative condition of the joints that is widely prevalent worldwide, resulting in significant pain, disability, and impaired quality of life. The diverse etiology and pathogenesis of OA can explain the paucity of viable preventive and disease-modifying strategies to counter it. Advances in genome-editing techniques may improve disease-modifying solutions by addressing inherited predisposing risk factors and the activity of inflammatory modulators. Recent progress on technologies such as CRISPR/Cas9 and cell-based genome-editing therapies targeting the genetic and epigenetic alternations in OA offer promising avenues for early diagnosis and the development of personalized therapies. The purpose of this literature review was to concisely summarize the genome-editing options against chronic degenerative joint conditions such as OA with a focus on the more recently emerging modalities, especially CRISPR/Cas9. Future advancements in novel genome-editing therapies may improve the efficacy of such targeted treatments.

Keywords: osteoarthritis; CRISPR/Cas9; miRNA; genome editing

1. Introduction

Osteoarthritis (OA) is a chronic disease affecting the joints of the body, especially the weight-bearing joints, chiefly the knees, hips, shoulders, and spine. OA is the most common type of degenerative arthritis, affecting over 30 million Americans [1]. It is also the second most expensive disease to treat in the US, costing $139.8 billion in 2013 [2]. As the fifth leading cause of disability in the US, OA has a significant impact on the quality of life.

In 2017, the Centers for Disease Control (CDC) published results on the prevalence of doctor-diagnosed arthritis from 2013 to 2015, including 54.4 million adults, nearly half of whom had activity limitations attributable to arthritis [3]. More alarmingly, as our US population ages, the number of cases is projected to increase to 78.4 million, or 25.9% of the population, by 2040 [4]. According to the World Health Organization (WHO), the United Nations has categorized OA as a priority disease in need of research into potential therapies. Given that between 2015 and 2050, the proportion of the world’s population over 60 years old will nearly double from 12% to 22%, an estimated 130 million people will suffer from OA worldwide (WHO, 2018).

The progression of OA includes the degradation of the hyaline articular cartilage at the ends of the articulating bones of the synovial joints. The articular cartilage, when healthy, functions to
With the increasing life span of the population in addition to the epidemic of obesity, the number of people affected by joint degeneration is expected to increase substantially [23–25]. Severe OA can prevent a person from being able to work, especially if their work involves putting stress on a specific joint for an extended duration. OA can result in significant physical, mental, emotional, and social challenges as well [26–28].

OA, characterized by joint stiffness, tenderness, swelling, and pain, is not a single disease per se [14]. It is, rather, a complex disease consisting of a group of conditions with multiple pathways that all result ultimately in progressive, irreversible joint failure as the outcome. Many susceptibility factors play a part in the pathogenesis of OA, such as age, gender, and weight [18–20]. Old age, female gender, repetitive joint stress, injury, joint laxity, high body weight, and osteoporosis all contribute to OA [21,22]. With the increasing life span of the population in addition to the epidemic of obesity, the number of people affected by joint degeneration is expected to increase substantially [23–25]. Severe OA can prevent a person from being able to work, especially if their work involves putting stress on a specific joint for an extended duration. OA can result in significant physical, mental, emotional, and social challenges as well [26–28].
Despite nonsurgical and surgical interventions, there is currently neither a cure for this disease nor a means to halt its inevitable progression [22,29]. Autologous chondrocyte transplantation has shown promise in clinical treatment, however, the process involves the harvest, culture, and transplant of cells grown in a monolayer (2D culture) [30–33]. Under these culture conditions, the risk of dedifferentiation of the chondrocytes and an altered phenotype is a major concern of tissue engineering [34].

2. Current Treatment Options and Limitations

The progressive erosion of articular cartilage is a prevalent symptom of OA [35]. Articular cartilage is made up of chondrocytes embedded within a collagenous extracellular matrix (ECM) [36]. Disruption of the articular cartilage prevents pain-free movement and affects the load-bearing abilities of the joint. Current treatments for OA can include intra-articular joint injections of steroids and arthroscopic lavage with debridement; however, these may have short-term benefits without long-term benefit to the cartilage [22,37,38]. Anti-inflammatory and analgesic drugs may help to address some of the symptoms of OA, but they do not tackle the fundamental pathologies involved in the inexorable degenerative process, in addition to having significant side effects associated with prolonged use [39–42]. Surgery and joint replacement, if possible in the early stages of OA, are expensive and may need to be performed multiple times during an individual’s life [22,43]. Alternative modalities of treatment may well be helpful in the short term, but may not be a sustainable strategy for OA treatment and potential prevention [44,45].

The best way to combat the root cause of joint degeneration in OA may be through the exploration of the various possibilities that genome editing offers [46,47]. There is increasing evidence that genetic and epigenetic modifications play a substantive role in OA; however, it has been difficult to separate the individual effects from the combined effects of genetic and environmental factors acting together to cause progressive joint degeneration [48–51]. Characterizing and analyzing the genetic factors underpinning the pathology of OA may provide viable options for the diagnosis, prognosis, and development of novel treatment targets for future personalized biological therapies.

3. CRISPR/Cas

Several gene therapy systems such as viral, engineered scaffold, and other approaches hold promise [52]. However, while such systems hold promise, the advantages are offset by some potential disadvantages. Here we focus on the CRISPR/Cas9 system, a very powerful gene therapy tool.

CRISPR/Cas is a novel, versatile, and promising genome-editing technique that is opening up new avenues and possibilities in the effective treatment of OA [53] and other degenerative joint diseases [54,55]. CRISPR is an acronym for “clustered regularly interspaced short palindromic repeats”, discovered through investigation of the prokaryotic adaptive immune system. It was identified as an effective system used by bacteria and archaea to remember infecting agents such as phage viruses and destroy them upon subsequent exposure, similarly to the memory cells in the human immune system. When paired with different proteins, specifically enzymes such as Cas, that are produced naturally by the prokaryotic cells, the CRISPR system can be used to make deletions, insertions, substitutions, or other changes at specific sites of the prokaryotic and eukaryotic genome [56,57]. From finding a cure for cancer, to treating sickle-cell disease, to growing drought- and pest-resistant crops, CRISPR has many exciting possibilities and potential in several fields [58].

The prokaryotic CRISPR/Cas system has three main components: a Cas nuclease, a crRNA (CRISPR RNA), and a tracrRNA (trans-activating crRNA). In bacterial cells, the CRISPR/Cas system works by recognizing the invading bacteriophage DNA, chopping it up into several pieces, and incorporating them into its DNA. These CRISPR pieces are then transcribed, generating a crRNA and a tracrRNA to create a double-stranded RNA structure that can recruit the Cas proteins. When the offending phage is encountered again, the CRISPR/Cas system is directed to a specific location on the foreign DNA because of a protospacer adjacent motif (PAM) short nucleotide base sequence which is upstream of the crRNA targeted sequence. The Cas protein is programmed to be the “molecular scissors”
of the system which carries out the cutting, splicing, and any other editing that is desired [59–61]. The therapeutic application of CRISPR/Cas is illustrated in Figure 2.

![Figure 2. CRISPR/Cas mechanism. Trans-activating RNA (orange) with CRISPR RNA (blue) the guide RNA. The guide RNA assembles with the Cas9 protein to form the CRISPR complex. Using the guide RNA for specificity, the CRISPR complex binds to the target DNA. Transgenic DNA can be inserted using homology arm inserts.](image)

The most widely used of the six major types of CRISPR/Cas system, the Type II system, is derived from the Streptococcus pyogenes bacteria. It uses the Cas9 protein because of its wide working range and efficiency [62]. The CRISPR/Cas9 system that is used currently by researchers and scientists worldwide consists of a single guide RNA (sgRNA) with a binding end (analogous to tracrRNA) for the Cas9 nuclease to attach and a targeting end (similar to crRNA) with nucleotide base pairs that are complementary to the DNA sequence that is meant to be edited (Figure 2). Only the targeting end of the sgRNA needs to be synthesized for any specific targeting sequence, while the binding end does not need to be redesigned every time, thus reducing the time needed to get the tool ready for editing. Cas9 recruitment to the exact DNA target sequence is mediated by the sgRNA. Cas9-induced double-stranded breaks (DSBs) are repaired either by spontaneously nonhomologous end joining (NHEJ) or by homology-directed repair (HDR) using a synthetic donor DNA template [63]. CRISPR/Cas RNA-guided DNA endonuclease genome targeting is much easier to design and apply when compared to other available site-specific editing tools using engineered nucleases such as transcription activator-like effector nuclease (TALENs) and zinc finger nucleases (ZFNs), which are controlled by protein–DNA interactions. CRISPR/Cas is also much more cost- and time-effective because researchers only need to code for a small section of sgRNA [64].

4. Mesenchymal Stem Cells and Tissue Regeneration

Tissue regeneration and self-renewal of articular cartilage, in general, is a very limited process [65]. The avascularity of articular cartilage may hinder progenitor cells access to the site of injured cartilage [66]). It may also limit molecular factors that are vital to extracellular matrix repair and homeostasis [67–70].

Chondrocytes originate from mesenchymal stem cells [71,72]. Bone-marrow-derived MSCs (BM-MSCs) have much promise in aiding articular cartilage repair due to their proximity to the joint, high differentiation capability, and ability to secrete different growth, anti-inflammatory, and immunomodulatory factors [73–77]. They could affect a clinically relevant improvement in joint pain and function. Additional studies are needed, however, to demonstrate the efficacy of cultured
versus noncultured BM-MSCs and the best ways to deliver them into the joint. MSCs derived from fetal cells also have therapeutic properties, but ethical concerns have been raised about using them for treatment and therapeutic applications [78,79]. Additional challenges arise due to the potential of fetal MSCs to differentiate into several different types of cells, which might be more difficult to control and direct [76,80,81]. The capabilities of MSCs are usually age-dependent. MSCs have a short lifespan but can secrete paracrine factors that may be beneficial in tissue regeneration [81,82]. In addition to BM-MSCs, MSCs derived from other sites such as adipose tissue can be isolated, expanded, characterized, and used to regenerate cartilage [83,84]. However, MSCs tend to form mechanically inferior fibrocartilage instead of the glassy, hyaline cartilage that covers the ends of bones at articulating joints [85].

5. Extracellular Vesicles

Genome-editing factors, packaged in engineered CRISPR/Cas9 complexes, can be enclosed in extracellular vesicles (EVs), for delivery to specific target cells [86,87]. EVs are composed of cellular constituents such as lipids, proteins, RNA, and DNA [86,88]. EVs may cross the blood–brain barrier, target cells in vivo, and protect their components from degradation in the circulatory system [87,89]. Their function is dependent upon their origin, and EVs derived from MSCs could have the potential to deliver contents to OA cells [90–93], as shown in Figure 3 [85,94,95]. The use of exosomes as a nonselective cell system may have limitations, including the delivery of contents to unintended cell targets. Possible solutions to this challenge include the design of targeted exosomes, as suggested by Bellavia and colleagues [96].

![Figure 3. Extracellular vesicle delivery of CRISPR/Cas9 in the treatment of OA. Inside a producer cell (left), engineered OA-targeted sgRNA transcription may occur. SgRNA combines with Cas9 to form CRISPR/Cas9 sgRNA complexes. CRISPR/Cas9 complexes load into extracellular vesicles with fluorescent tags containing a dimerization domain compatible with a dimerization domain in engineered CRISPR/Cas9 complexes. These fluorescent tags also contain targets for the target osteoarthritic cell (right). Loaded EVs attach to target cells and unload the CRISPR/Cas9 complexes, which are then transported to the nucleus to perform gene modification.](image)

Exogenous-cell-based therapy is gaining traction for the regeneration of articular cartilage over stimulation therapy such as electric stimulation of endogenous cartilage growth factors [97]. Exogenous cell therapy can be done through the delivery of chondrocytes (either autologous or allogeneic), mesenchymal stem cells (MSCs), or extracellular vesicles [98]. MSCs are used for regenerative medicine due to their ability to promote regeneration based on environmental signals at sites of injury. As inhibitors of the immune system and multilineage differentiators, MSCs are an important alternative...
cell source for articular cartilage repair and regeneration [97]. MSCs derived from the synovial membranes of joints have been shown to be more effective in terms of articular cartilage formation in vitro studies when compared to MSCs from other tissues, joint and nonjoint [99,100].

In vitro studies performed in mice showed that microparticles and exosomes, which are EVs derived from MSCs, exerted similar chondroprotective and anti-inflammatory functions, protecting mice from developing osteoarthritis and reproducing the main therapeutic effect of reducing symptoms [101, 102]. Thus, a combinatorial approach to the treatment of OA may be feasible.

6. Potential CRISPR/Cas9 Molecular Targets for the Treatment of Osteoarthritis

Cell therapy has great potential to help treat OA, but inflammation can prevent new articular cartilage from forming after the introduction of stem cells. Inflammation and inflammatory modulators must be addressed in the treatment of OA, and these inflammatory modulators may serve as targets for CRISPR/Cas9 strategies [103]. Table 1 identifies potential targets for CRISPR/Cas9 editing and the laboratories that are making progress in the use of CRISPR/Cas9 techniques in OA treatment.

IL-1β is a pro-inflammatory cytokine secreted primarily by neutrophils. IL-1β induces the expression of many OA-related genes and other cytokines, including tumor necrosis factor-alpha (TNFα) [104]. Current OA therapies target TNFα, however, deleterious side effects occur due to TNFα’s role in facilitating many other functions [105,106]. Human articular cartilage (hAC) exposed to TNFα displays increased levels of expression of interleukin IL-1β [105,106]. Karlsen and colleagues, in their 2016 study, were able to silence the IL-1β cytokine receptor (IL1-R1) in hACs to determine its effect on inflammation and the redifferentiation potential of the hACs after exposure to the interleukin IL-1β. The hACs were isolated from cartilage, and CRISPR/Cas9 was used to knock out the IL1-R1 receptor and insert a puromycin-resistance gene to allow the selection of the knockout cells. The colonies of knockout cells were expanded and exposed to recombinant IL-1β and TNFα to assess their response. The results showed that the addition of recombinant IL-1β increased inflammation to high levels in the control group, as expected. However, in the knockout group, exposure to recombinant IL-1β did not cause measurable inflammation. Therefore, the therapeutic knockdown of IL1-R1 in articular cartilage cells in vitro prior to re-injection into the body may improve cell-therapy results [106].

**Table 1. Potential CRISPR/Cas9 molecular targets for CRISPR/Cas treatment of osteoarthritis.**

| Gene Symbol | Gene Name | Function | Reference |
|-------------|-----------|----------|-----------|
| IL1-β | Interleukin 1 beta | Inflammation | Karlsen, 2016 [106] Zhao, 2019 [53] Guilak [73] |
| IL1-R1 | Interleukin 1 beta receptor | Inflammation | Karlsen, 2016 [106] |
| BGLAP | Osteocalcin | Trabecular bone formation | Lambert, 2016 [107] |
| miR-140 | Micro RNA 140 | Chondrocyte homeostasis | Asahara, 2016 [108] |
| Has2 | Hyaluronan synthase 2 | Chondrocyte accumulation of aggrecan | Huang, 2016 [109] |
| sTNFR1α | Soluble Tumor necrosis factor receptor 1 | TNF antagonist | Brunger, 2017 [110] |
| IL1RA | Interleukin 1 beta receptor antagonist | IL-1 beta antagonist | Brunger, 2017 [110] |
| PRG4 | Lubricin | Joint lubrication | Khakshooy, 2017 [111] |
| Runx2 | Runt Related Transcription Factor 2 | Osteoblast differentiation | Rice, 2018 [112] |
| Hrdl | E3 ubiquitin-protein ligase hrd-like protein 1 | Protein turnover and proteasomal degradation | Ye, 2018 [113] |
| Mrnp13 | Matrix metalloprotein 13 | Tissue degradation | Seidl, 2019 [114] Zhao, 2019 [53] |
| Cx43 | Connexin 43 | Gap junction protein | Varela-Eirín M, 2018 [115] |
| NGF | Nerve growth factor | Pain sensitivity | Zhao, 2019 [53] |
| Cbx4 | Chromobox 4 | Nucleolar homeostasis | Ren, 2019 [116] |
| Foxd1 | Forkhead box D1 | Transcription factor | Fu, 2019 [117] |
| YAP | Yes-associated protein 1 | Mechanosensing transcription factor | Fu, 2019 [117] |
Recent gene-editing efforts have targeted cellular senescence. Ren and colleagues found that by targeting CBX4, cellular senescence could be alleviated, with positive outcomes for OA [116]. FOXD1 is a transcription factor that can be regulated by YAP. Recent research indicates that the upregulation of FOXD1 by YAP may hold promise for OA treatment by alleviating senescence [117]. Further studies that focused on connexin 43 modulation were able to demonstrate that the attenuation of cellular senescence could promote the regenerative capacity of cells and improve tissue quality in OA [115].

Degradative enzymes such as matrix metalloproteinases (MMP) play important roles in joint health. Seidl and colleagues utilized CRISPR/Cas9 to modify the MMP13 levels in human chondrocytes and found that by reducing the level of MMP activity, cells were able to accumulate higher levels of the beneficial type II collagen to strengthen the extracellular matrix of the articular cartilage [114].

7. Additional Emerging Targets for the Treatment of Osteoarthritis Using CRISPR/Cas9

While a significant focus is placed on cartilage and the chondrocytes that maintain articular cartilage, there is wide agreement that OA is not simply a disease of the cartilage, but rather of the entire joint, and all of the specific tissue types within the joint play essential roles. Osteocalcin, a small protein hormone secreted by the osteoblasts of the bone, has been studied recently for its endocrine functions, which impact several physiological processes. Lambert and colleagues found in their 2016 study that by applying CRISPR/Cas9 technologies to osteocalcin expression, they were able to improve bone biomechanics and increase the trabecular bone in a rat model system [107].

Additional potential targets for therapy have been identified using CRISPR/Cas9 technology. For example, CRISPR/Cas9 knockout of hyaluronan synthase 2 (HAS2) in rat chondrocytes demonstrated the importance of the glycosaminoglycan hyaluronan, for the retention of aggrecan, a proteoglycan necessary for the functional integrity of the articular cartilage [109]. CRISPR/Cas9 can, therefore, provide fundamental information about the molecular mechanisms required for healthy joint tissue in addition to potential use as a direct treatment.

8. Limitations and Future Considerations

The CRISPR/Cas9 system is being used in a wide range of applications and many studies. However, notwithstanding its meteoric rise in a short period of time and its potential applications in medicine and beyond, it, like other genome-editing tools, does come with limitations and concerns, ethical and otherwise. One of these limitations is the effective targeting range, as the sgRNA can only bind to a region near a specific PAM sequence on the DNA. The PAM sequence for Cas9 is 5′-NGG-3′, where “N” can be any nucleotide base, but the third base must be G. This can greatly reduce the potential target locations available to make DNA edits such as insertions or deletions. In experiments conducted by Nishimasu and colleagues, a Cas9 with a more relaxed preference for the PAM third base resulted in the recognition of an NGD PAM instead of an NGG PAM requirement. This effectively increased the potential targets for Cas9 nuclease, as the NGD sequence occurs more frequently in human DNA than NGG sequences. The engineered Cas9 in this instance had a wider range and increased cleavage specificity, reducing instances of off-target incisions. The new Cas, termed SpCas9-NG, can bind to A, G, or T in the 3rd base of the PAM sequence [118].

MicroRNAs (miRNAs), small, non-coding RNA molecules, may help to regulate inflammation, promote MSC differentiation, and ensure the homeostasis of cartilage [119]. As a key factor in epigenetic regulation, miRNAs can change the gene expression without modifying the sequence of the DNA that encodes proteins [120]. This may be a much safer way to modulate gene expression since the genome sequence does not change, and the gene expression pattern may still be inheritable from one cell generation to the next [85]. miRNAs may be used in combination with CRISPR/Cas9 and EVs to design patient-specific approaches to the treatment of OA [103].
9. Conclusions

Investigators and practitioners the world over are working toward a better understanding of the basis of degenerative joint diseases such as OA. Devising ways to alter or modify the relevant genes impacting the joint articular cartilage may lead to the development of successful, safe, and effective therapies to halt the progress, treat, or even prevent the occurrence of OA and other debilitating joint disorders in humans. CRISPR/Cas9, MSCs, EVs, and miRNAs may all play key roles in future treatments.

Author Contributions: Conceptualization, A.S.T. and J.T.O.; methodology, A.S.T. and J.T.O.; investigation, A.S.T.; writing—original draft preparation, A.S.T. and J.T.O.; writing—review and editing, C.K.F., A.G.C., J.T.O.; illustrations, S.M.F., M.J.H., A.G.C., and K.D.G.; supervision, J.T.O.; funding acquisition, J.T.O. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by NIH NIGMS, grant number P20GM109095 and P20GM103408.

Acknowledgments: Authors wish to acknowledge support from the Institutional Development Awards (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under Grants #P20GM103408, P20GM109095, and 1C06RR020533. We also acknowledge support from The Biomolecular Research Center at Boise State with funding from the National Science Foundation, Grants #0619793 and #0923535; the M. J. Murdock Charitable Trust; Lori and Duane Stueckle, and the Idaho State Board of Education.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Abbreviations

| Acronym | Description |
|---------|-------------|
| OA      | Osteoarthritis |
| CRISPR  | Clustered Regularly Interspaced Short Palindromic Repeats |
| Cas     | Cas nuclease |
| crRNA   | CRISPR RNA |
| tracrRNA| trans-activating crRNA |
| PAM     | protospacer adjacent motif |
| sgRNA   | single guide RNA |
| MSC     | Mesenchymal stem cells |
| miRNA   | Micro RNA |
| EV      | Extracellular vesicles |
| IL-1β   | Interleukin 1 beta |
| TNFα    | Tumor Necrosis Factor |
| Hac     | Human articular cartilage |
| IL1-R1  | IL-1β cytokine receptor 1 |
| BGLAP   | Osteocalcin |
| Has2    | Hyaluronan synthase 2 |
| PRG4    | Lubricin |
| Runx2   | Runt Related Transcription Factor 2 |
| Hrdl    | E3 ubiquitin-protein ligase hrd-like protein 1 |
| Mmp13   | Matrix metalloprotein 13 |
| Cx43    | Connexin 43 |
| Cbx4    | Chromobox 4 |
| Foxd1   | Forkhead box D1 |
| YAP     | Yes-associated protein 1 |
| NHEJ    | Non-homologous end joining |
| HDR     | Homology Directed Repair |
| TALENs  | Transcription activator-like effector nucleases |
| ZFN     | Zinc finger nucleases |
References

1. Bitton, R. The economic burden of osteoarthritis. *Am. J. Manag. Care* 2009, 15, S230–S235. [PubMed]
2. Murphy, L.B.; Cisternas, M.G.; Pasta, D.J.; Helmick, C.G.; Yelin, E.H. Medical Expenditures and Earnings Losses Among US Adults with Arthritis in 2013. *Arthritis Care Res.* 2018, 70, 869–876. [CrossRef] [PubMed]
3. Barbour, K.E.; Helmick, C.G.; Boring, M.; Brady, T.J. Vital Signs: Prevalence of Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation—United States, 2013–2015. *MMWR. Morb. Mortal. Wkly. Rep.* 2017, 66, 246–253. [CrossRef] [PubMed]
4. Hootman, J.M.; Helmick, C.G.; Barbour, K.E.; Theis, K.A.; Boring, M.A. Updated Projected Prevalence of Self-Reported Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation Among US Adults, 2015–2040. *Arthritis Rheumatol.* 2016, 68, 1582–1587. [CrossRef]
5. Sophia Fox, A.J.; Bedi, A.; Rodeo, S.A. The basic science of articular cartilage: Structure, composition, and function. *Sports Health* 2009, 1, 461–468. [CrossRef]
6. Medvedeva, E.V.; Grebenik, E.A.; Gornostaeva, S.N.; Telpuhov, V.I.; Lychagin, A.V.; Timashev, P.S.; Chagin, A.S. Repair of damaged articular cartilage: Current approaches and future directions. *Int. J. Mol. Sci.* 2018, 19, 2366. [CrossRef] [PubMed]
7. Karuppal, R. Current concepts in the articular cartilage repair and regeneration. *J. Orthop.* 2017, 14, A1–A3. [CrossRef]
8. Kreuz, P.C.; Steinwachs, M.R.; Erggelet, C.; Krause, S.J.; Konrad, G.; Uhl, M.; Südkamp, N. Results after microfracture of full-thickness chondral defects in different compartments in the knee. *Osteoarthr. Cartil.* 2006, 14, 1119–1125. [CrossRef]
9. Armiento, A.R.; Alini, M.; Stoddart, M.J. Articular fibrocartilage—Why does hyaline cartilage fail to repair? *Adv. Drug Deliv. Rev.* 2019, 146, 289–305. [CrossRef]
10. Tamer, T.M. Hyaluronan and synovial joint: Function, distribution and healing. *Interdiscip. Toxicol.* 2013, 6, 111–125. [CrossRef]
11. Seror, J.; Zhu, L.; Goldberg, R.; Day, A.J.; Klein, J. Supramolecular synergy in the boundary lubrication of synovial joints. *Nat. Commun.* 2015, 6, 1–7. [CrossRef] [PubMed]
12. Odgren, P.R.; Witwicka, H.; Reyes-Gutierrez, P. The cast of clasts: Catabolism and vascular invasion during bone growth, repair, and disease by osteoclasts, chondroclasts, and septoclasts. *Connect. Tissue Res.* 2016, 57, 161–174. [CrossRef] [PubMed]
13. Buckwalter, J.A.; Mankin, H.J. Articular cartilage: Degeneration and osteoarthritis, repair, regeneration, and transplantation. *Instr. Course Lect.* 1998, 47, 487–504. [PubMed]
14. Harrell, C.R.; Markovic, B.S.; Fellabaum, C.; Arsenijevic, A.; Volarevic, V. Mesenchymal stem cell-based therapy of osteoarthritis: Current knowledge and future perspectives. *Biomed. Pharmacother.* 2019, 109, 2318–2326. [CrossRef]
15. Sandell, L.J.; Aigner, T. Articular cartilage and changes in arthritis. An introduction: Cell biology of osteoarthritis. *Arthritis Res.* 2001, 3, 107–113. [CrossRef]
16. Berenbaum, F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). *Osteoarthr. Cartil.* 2013, 21, 16–21. [CrossRef]
17. Fukui, N.; Purple, C.R.; Sandell, L.J. Cell biology of osteoarthritis: The chondrocyte’s response to injury. *Curr. Rheumatol. Rep.* 2001, 3, 496–505. [CrossRef]
18. Andriacchi, T.P.; Mündermann, A.; Smith, R.L.; Alexander, E.J.; Dyrby, C.O.; Koo, S. A framework for the in vivo pathomechanics of osteoarthritis at the knee. *Ann. Biomed. Eng.* 2004, 32, 447–457. [CrossRef]
19. DeFrate, L.E.; Kim-Wang, S.Y.; Englander, Z.A.; McNulty, A.L. Osteoarthritis year in review 2018: Mechanics. *Osteoarthr. Cartil.* 2019, 27, 392–400. [CrossRef]
20. Musumeci, G.; Aiello, F.C.; Szychlinska, M.A.; Di Rosa, M.; Castrogiovanni, P.; Mobasher, A. Osteoarthritis in the XXIst century: Risk factors and behaviours that influence disease onset and progression. *Int. J. Mol. Sci.* 2015, 16, 6093–6112. [CrossRef]
21. Qin, Y.X.; Lam, H.Y. Intramedullary pressure and matrix strain induced by oscillatory skeletal muscle stimulation and its potential in adaptation. *J. Biomech.* 2009, 42, 140–145. [CrossRef] [PubMed]
22. Anandacoomarasamy, A.; March, L. Current evidence for osteoarthritis treatments. *Ther. Adv. Musculoskelet. Dis.* 2010, 2, 17–28. [CrossRef] [PubMed]
23. Songer, T.J.; LaPorte, R.E. Disabilities due to injury in the military. *Am. J. Prev. Med.* 2000, 18, 33–40. [CrossRef]

24. Ma, V.Y.; Chan, L.; Carruthers, K.J. Incidence, prevalence, costs, and impact on disability of common conditions requiring rehabilitation in the united states: Stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, osteoarthritis, rheumatoid arthritis, limb loss, and back pa. *Arch. Phys. Med. Rehabil.* 2014, 95, 986–995. [CrossRef]

25. Losina, E.; Walensky, R.P.; Reichmann, W.M.; Holt, H.L.; Gerlovin, H.; Solomon, D.H.; Jordan, J.M.; Hunter, D.J.; Suter, L.G.; Weinstein, A.M.; et al. Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans. *Ann. Intern. Med.* 2011, 154, 217–226. [CrossRef]

26. Park, H.M.; Kim, H.S.; Lee, Y.J. Knee osteoarthritis and its association with mental health and health-related quality of life: A nationwide cross-sectional study. *Geriatr. Gerontol. Int.* 2020, 20, 379–383. [CrossRef]

27. Sharma, M.; Jamieson, C.; Johnson, M.; Molloy, M.P.; Henderson, B.R. Specific Armadillo Repeat Sequences Facilitate β-Catenin Nuclear Transport in Live Cells via Direct Binding to Nucleoporins Nup62, Nup153, and RanBP2/Nup358. *J. Biol. Chem.* 2012, 287, 819–831. [CrossRef]

28. Luong, M.L.N.; Cleveland, R.J.; Nyrop, K.A.; Callahan, L.F. Social determinants and osteoarthritis outcomes. *Aging Health* 2012, 8, 413–437. [CrossRef]

29. Grässel, S.; Muschter, D. Recent advances in the treatment of osteoarthritis. *F1000Research* 2020, 9, 325. [CrossRef]

30. Brittberg, M.; Lindahl, A.; Nilsson, A.; Ohlsson, C.; Isaksson, O.; Peterson, L. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. *N. Engl. J. Med.* 1994, 331, 889–895. [CrossRef]

31. Dozin, B.; Malpeli, M.; Cancetta, R.; Bruzzi, P.; Calcagno, L.; Piana, F.; Kon, E.; Maracci, M. Comparative evaluation of autologous chondrocyte implantation and mosaicplasty: A multicentered randomized clinical trial. *Clin. J. Sport Med.* 2005, 15, 220–226. [CrossRef] [PubMed]

32. Dewan, A.K.; Gibson, M.A.; Elisseev, J.H.; Trice, M.E. Evolution of autologous chondrocyte repair and comparison to other cartilage repair techniques. *Biomed Res. Int.* 2014, 2014, 272481. [CrossRef] [PubMed]

33. Stein, S.; Strauss, E.; Bosco, J. Advances in the Surgical Management of Articular Cartilage Defects: Autologous Chondrocyte Implantation Techniques in the Pipeline. *Cartilage* 2013, 4, 12–19. [CrossRef] [PubMed]

34. Hubka, K.M.; Dahlin, R.L.; Meretoja, V.V.; Kasper, F.K.; Mikos, A.G. Enhancing Chondrogenic Phenotype for Cartilage Tissue Engineering: Monoculture and Coculture of Articular Chondrocytes and Mesenchymal Stem Cells. *Tissue Eng. Part B Rev.* 2014, 20, 641–654. [CrossRef]

35. Goldring, M.B. Articular Cartilage Degradation in Osteoarthritis. *HSS J.* 2012, 8, 7–9. [CrossRef]

36. Gao, Y.; Liu, S.; Huang, J.; Guo, W.; Chen, J.; Zhang, L.; Zhao, B.; Peng, J.; Wang, A.; Wang, Y.; et al. The ECM-Cell Interaction of Cartilage Extracellular Matrix on Chondrocytes. *Biomed Res. Int.* 2014, 2014, 648459. [CrossRef]

37. Gesslein, M.; Merkl, C.; Bail, H.J.; Krutsch, V.; Biber, R.; Schuster, P. Refixation of Large Osteochondral Fractures After Patella Dislocation Shows Better Mid- to Long-Term Outcome Compared with Debridement. *Cartilage* 2019, 13. [CrossRef]

38. Ravaud, P.; Moulinier, L.; Girardeau, B.; Ayal, X.; Guerin, C.; Noel, E.; Thomas, P.; Fautrel, B.; Mazieres, B.; Dougdos, M. Effects of joint lavage and steroid injection in patients with osteoarthritis of the knee: Results of a multicenter, randomized, controlled trial. *Arthritis Rheum.* 1999, 42, 475–482. [CrossRef]

39. Ghouri, A.; Conaghan, P.G. Treating osteoarthritis pain: Recent approaches using pharmacological therapies. *Clin. Exp. Rheumatol.* 2019, 37, 124–129.

40. Jaswal, A.P.; Bandyopadhyay, A. Re-examining osteoarthritis therapy from a developmental biologist’s perspective. *Biochem. Pharmacol.* 2019, 165, 17–23. [CrossRef]

41. Honvo, G.; Leclercq, V.; Geerinck, A.; Thomas, T.; Veronese, N.; Charles, A.; Rabenda, V.; Beaudart, C.; Cooper, C.; Reginster, J.Y.; et al. Safety of Topical Non-steroidal Anti-Inflammatory Drugs in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. *Drugs Aging* 2019, 36, 45–64. [CrossRef] [PubMed]

42. Zhang, W.; Robertson, W.B.; Zhao, J.; Chen, W.; Xu, J. Emerging trend in the pharmacotherapy of osteoarthritis. *Front. Endocrinol.* 2019, 10, 431. [CrossRef] [PubMed]

43. Palsis, J.A.; Brehmer, T.S.; Pellegrini, V.D.; Drew, J.M.; Sachs, B.L. The cost of joint replacement comparing two approaches to evaluating costs of total hip and knee arthroplasty. *J. Bone Jt. Surg.-Am. Vol.* 2018, 100, 326–333. [CrossRef] [PubMed]
44. DeRogatis, M.; Anis, H.K.; Sodhi, N.; Ehirorobo, J.O.; Chuhtai, M.; Bhave, A.; Mont, M.A. Non-operative treatment options for knee osteoarthritis. *Ann. Transl. Med.* **2019**, *7* (Suppl 7), S245. [CrossRef]  
45. Deyle, G.D.; Allen, C.S.; Allison, S.C.; Gill, N.W.; Hando, B.R.; Petersen, E.J.; Dusenberry, D.I.; Rhon, D.I. Physical therapy versus glucocorticoid injection for osteoarthritis of the knee. *N. Engl. J. Med.* **2020**, *382*, 1420–1429. [CrossRef] [PubMed]  
46. Hermann, W.; Lambova, S.; Müller-Ladner, U. Current Treatment Options for Osteoarthritis. *Curr. Rheumatol. Rev.* **2018**, *14*, 108–116. [CrossRef]  
47. Choi, Y.R.; Collins, K.H.; Lee, J.W.; Kang, H.J.; Guilak, F. Genome Engineering for Osteoarthritis: From Designer Cells to Disease-Modifying Drugs. *Tissue Eng. Regen. Med.* **2019**, *1*, 1–9. [CrossRef]  
48. Shen, J.; Abu-Amer, Y.; O’Keefe, R.J.; McAlinden, A. Inflammation and epigenetic regulation in osteoarthritis. *Connect. Tissue Res.* **2017**, *58*, 49–63. [CrossRef]  
49. Im, G.-I.; Choi, Y.-J. Epigenetics in osteoarthritis and its implication for future therapeutics. *Expert Opin. Biol. Ther.* **2013**, *13*, 713–721. [CrossRef]  
50. Garcia-Ibarbia, C.; Delgado-Calle, J.; Casafont, I.; Velasco, J.; Arozamena, J.; Pérez-Núñez, M.I.; Alonso, M.A.; Berciano, M.T.; Ortiz, F.; Pérez-Castrillón, J.L.; et al. Contribution of genetic and epigenetic mechanisms to Wnt pathway activity in prevalent skeletal disorders. *Gene* **2013**, *532*, 165–172. [CrossRef]  
51. Simon, T.C.; Jeffries, M.A. The Epigenomic Landscape in Osteoarthritis. *Curr. Rheumatol. Rep.* **2017**, *19*, 30. [CrossRef] [PubMed]  
52. Bellavia, D.; Veronesi, F.; Carina, V.; Costa, V.; Raimondi, L.; De Luca, A.; Alessandro, R.; Fini, M.; Giavaresi, G. Gene therapy for chondral and osteochondral regeneration: Is the future now? *Cell. Mol. Life Sci.* **2018**, *75*, 649–667. [CrossRef] [PubMed]  
53. Zhao, L.; Huang, J.; Fan, Y.; Li, J.; You, T.; He, S.; Xiao, G.; Chen, D. Exploration of CRISPR/Cas9-based gene editing as therapy for osteoarthritis. *Ann. Rheum. Dis.* **2019**, *78*, 676–682. [CrossRef] [PubMed]  
54. Adkar, S.S.; Brunger, J.M.; Willard, V.P.; Wu, C.-L.; Gersbach, C.A.; Guilak, F. Genome Engineering for Personalized Arthritis Therapeutics. *Trends Mol. Med.* **2017**, *23*, 917–931. [CrossRef] [PubMed]  
55. Mali, P.; Esvelt, K.M.; Church, G.M. Cas9 for engineering biology. *Nat. Methods* **2013**, *10*, 957–963. [CrossRef]  
56. Karimian, A.; Azizian, K.; Parsian, H.; Rafieian, S.; Shafiei-Irannejad, V.; Kheyrollah, M.; Yousefi, M.; Majidinia, M.; Yousefi, B. CRISPR/Cas9 technology as a potent molecular tool for gene therapy. *J. Cell. Physiol.* **2019**, *234*, 12267–12277. [CrossRef]  
57. Magee, C.L.; Kleyn, P.W.; Monks, B.M.; Betz, U.; Basnet, S. Pre-existing technological core and roots for the CRISPR breakthrough. *PLoS ONE* **2018**, *13*, e0198541. [CrossRef]  
58. Broeders, M.; Herrero-Hernandez, P.; Ernst, M.P.T.; van der Ploeg, A.T.; Pijnappel, W.W.M.P. Sharpening the pre-existing technological core and roots for the CRISPR breakthrough. *J. Genet. Genom.* **2018**, *65*, 713–721. [CrossRef]  
59. Adli, M. The CRISPR tool kit for genome editing and beyond. *Nat. Commun.* **2018**, *9*, 1–3. [CrossRef]  
60. Khan, S.; Mahmood, M.S.; Rahman, S.U.; Zafar, H.; Habibullah, S.; Khan, Z.; Ahmad, A. CRISPR/Cas9: The Jedi against the dark empire of diseases. *J. Biomed. Sci.* **2018**, *25*, 29. [CrossRef] [PubMed]  
61. Mei, Y.; Wang, Y.; Chen, H.; Sun, Z.S.; Ju, X.-D. Recent Progress in CRISPR/Cas9 Technology. *J. Genet. Genom.* **2016**, *43*, 63–75. [CrossRef] [PubMed]  
62. Sabel, D.K.; Mittal, A.; Chitkar, D. CRISPR/Cas System for Genome Editing: Progress and Prospects as a Therapeutic Tool. *J. Pharmaco exp. Ther.* **2019**, *370*, 725–735. [CrossRef] [PubMed]  
63. Doench, J.G.; Fusi, N.; Sullender, M.; Hegde, M.; Vainberg, E.W.; Donovan, K.F.; Smith, I.; Tothova, Z.; Wilen, C.; Orchard, R.; et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. *Nat. Biotechnol.* **2016**, *34*, 184–191. [CrossRef]  
64. Iwamoto, M.; Ohta, Y.; Larmour, C.; Enomoto-Iwamoto, M. Toward regeneration of articular cartilage. *Birth Defects Res. Part C-Embryo Today Rev.* **2013**, *99*, 192–202. [CrossRef]  
65. Grimaud, E.; Blanchard, F.; Charrier, C.; Gouin, F.; Redini, F.; Heymann, D. Leukaemia inhibitory factor (lif) is expressed in hypertrophic chondrocytes and vascular sprouts during osteogenesis. *Cytokine* **2002**, *20*, 224–230. [CrossRef]  
66. Loeser, R.F. Aging and osteoarthritis: The role of chondrocyte senescence and aging changes in the cartilage matrix. *Osteoarthr. Cartil.* **2009**, *17*, 971–979. [CrossRef]
68. Shi, Y.; Hu, X.; Cheng, J.; Zhang, X.; Zhao, F.; Shi, W.; Ren, B.; Yu, H.; Yang, P.; Li, Z.; et al. A small molecule promotes cartilage extracellular matrix generation and inhibits osteoarthritis development. *Nat. Commun.* 2019, 10, 1–4. [CrossRef]

69. Akkiraju, H.; Nohe, A. Role of chondrocytes in cartilage formation, progression of osteoarthritis and cartilage regeneration. *J. Dev. Biol.* 2015, 3, 177–192. [CrossRef]

70. Chittiboyina, S.; Bai, Y.; Lelièvre, S.A. Microenvironment-cell nucleus relationship in the context of oxidative stress. *Front. Cell Dev. Biol.* 2018, 6, 23. [CrossRef]

71. Jiang, Y.; Tuan, R.S. Origin and function of cartilage stem/progenitor cells in osteoarthritis. *Nat. Rev. Rheumatol.* 2015, 11, 206. [CrossRef] [PubMed]

72. de Crombrugghe, B.; Lefebvre, V.; Nakashima, K. Regulatory mechanisms in the pathways of cartilage and bone formation. *Curr. Opin. Cell Biol.* 2001, 13, 721–727. [CrossRef]

73. Guilak, F.; Pfredehirt, L.; Ross, A.K.; Choi, Y.; Collins, K.; Nims, R.J.; Katz, D.B.; Klimak, M.; Tabbaa, S.; Pham, C.T.N. Designer Stem Cells: Genome Engineering and the Next Generation of Cell-Based Therapies. *J. Orthop. Res.* 2019, 37, 1287–1293. [CrossRef] [PubMed]

74. García-Álvarez, F.; Alegre-Aguarón, E.; Desportes, P.; Royo-Cañas, M.; Castiella, T.; Larrad, L.; Martínez-Lorenzo, M.J. Chondrogenic differentiation in femoral bone marrow-derived mesenchymal cells (MSC) from elderly patients suffering osteoarthritis or femoral fracture. *Arch. Gerontol. Geriatr.* 2011, 52, 239–242. [CrossRef]

75. Tuan, R.S.; Boland, G.; Tuli, R. Adult mesenchymal stem cells and cell-based tissue engineering, *Arthritis Res. Ther.* 2003, 5, 1–4. [CrossRef]

76. Fellows, C.R.; Matta, C.; Zakany, R.; Khan, I.M.; Mobasheri, A. Adipose, bone marrow and synovial joint-derived mesenchymal stem cells for cartilage repair. *Front. Genet.* 2015, 6, 96. [CrossRef]

77. O’Donoghue, K.; Fisk, N.M. Fetal stem cells. *Front. Cell Dev. Biol.* 2016, 4, 25. [CrossRef]

78. Zhang, R.; Ma, J.; Han, J.; Zhang, W.; Ma, J. Mesenchymal stem cell related therapies for cartilage lesions and osteoarthritis. *Am. J. Transl. Res.* 2019, 11, 6275. [PubMed]

79. Zhang, R.; Ma, J.; Han, J.; Zhang, W.; Ma, J. Mesenchymal stem cell related therapies for cartilage lesions and osteoarthritis. *Am. J. Transl. Res.* 2019, 11, 6275. [PubMed]

80. Park, D.Y.; Min, B.H.; Park, S.R.; Oh, H.J.; Truong, M.D.; Kim, M.; Choi, J.Y.; Park, I.S.; Choi, B.H. Engineered cartilage utilizing fetal cartilage-derived progenitor cells for cartilage repair. *Sci. Rep.* 2020, 10, 5722. [CrossRef] [PubMed]

81. Zhang, R.; Ma, J.; Han, J.; Zhang, W.; Ma, J. Mesenchymal stem cell related therapies for cartilage lesions and osteoarthritis. *Am. J. Transl. Res.* 2019, 11, 6275. [PubMed]

82. McGonagle, D.; Baboolal, T.G.; Jones, E. Native joint-resident mesenchymal stem cells for cartilage repair in osteoarthritis. *Nat. Rev. Rheumatol.* 2017, 13, 719–730. [CrossRef] [PubMed]

83. Jo, C.H.; Lee, Y.G.; Shin, W.H.; Kim, H.; Choi, J.W.; Jeong, E.C.; Kim, J.E.; Shim, H.; Shin, J.S.; Shin, I.S.; et al. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: A proof-of-concept clinical trial. *Stem Cells Clin. Pract.* 2014, 32, 1254–1266. [CrossRef] [PubMed]

84. Damia, E.; Chicharro, D.; Lopez, S.; Cuervo, B.; Rubio, M.; Sopena, J.J.; Vilar, J.M.; Carrillo, J.M. Adipose-derived mesenchymal stem cells: Are they a good therapeutic strategy for osteoarthritis? *Int. J. Mol. Sci.* 2018, 19, 1926. [CrossRef]

85. Lee, W.Y.-w.; Wang, B. Cartilage repair by mesenchymal stem cells: Clinical trial update and perspectives. *J. Orthop. Transl.* 2017, 9, 76–88. [CrossRef]

86. Gee, P.; Lung, M.S.Y.; Okuzaki, Y.; Sasakiwa, N.; Iwatsuki, T.; Makita, Y.; Hozumi, H.; Miura, Y.; Yang, L.F.; Iwasaki, M.; et al. Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping. *Nat. Commun.* 2020, 11, 1–18. [CrossRef]

87. de Jong, O.G.; Murphy, D.E.; Mäger, I.; Willms, E.; García-Guerra, A.; Gitz-Francois, J.J.; Lefferts, J.; Gupta, D.; Steenbeek, S.C.; van Rheenen, J.; et al. A CRISPR-Cas9-based reporter system for single-cell detection of extracellular vesicle-mediated functional transfer of RNA. *Nat. Commun.* 2020, 11, 1–3. [CrossRef]

88. Campbell, L.A.; Coke, L.M.; Richie, C.T.; Fortuno, L.V.; Park, A.Y.; Harvey, B.K. Gelsele-Mediated Delivery of CRISPR/Cas9 Ribonucleoprotein Complex for Inactivating the HIV Provirus. *Mol. Ther.* 2019, 27, 151–163. [CrossRef]
91. Levy, O.; Zhao, W.; Mortensen, L.; LeBlanc, S.; Tsang, K.; Fu, M.; Phillips, J.A.; Sagar, V.; Anandakumaran, P.; Ngai, J.; et al. mRNA-engineered mesenchymal stem cells for targeted delivery of interleukin-10 to sites of inflammation. *Blood* 2013, 122, e23–e32. [CrossRef] [PubMed]

92. Ragni, E.; Banfi, F.; Barilani, M.; Cherubini, A.; Parazzi, V.; Larghi, P.; Dolo, V.; Bollati, V.; Lazzari, L. Extracellular Vesicle-Shuttled mRNA in Mesenchymal Stem Cell Communication. *Stem Cells* 2017, 35, 1093–1105. [CrossRef] [PubMed]

93. Martin-Rufino, J.D.; Espinosa-Lara, N.; Osugui, L.; Sanchez-Guijo, F. Targeting the Immune System with Exosomes: New Promises for the Management of Cancer. *Acta-Gen. Subj.* 2018, 40, 74–80. [CrossRef]

94. Wang, Y.; Yu, D.; Liu, Z.; Zhou, F.; Dai, J.; Wu, B.; Zhou, J.; Heng, B.C.; Zou, X.H.; Ouyang, H.; et al. Exosomes from embryonic mesenchymal stem cells alleviate osteoarthritis through balancing synthesis and degradation of cartilage extracellular matrix. *Stem Cell Res. Ther.* 2017, 8, 189. [CrossRef] [PubMed]

95. Murphy, C.; Withrow, J.; Hunter, M.; Liu, Y.; Tang, Y.L.; Fulzele, S.; Hamrick, M.W. Emerging role of extracellular vesicles in musculoskeletal diseases. *J. Musculoskelet. Neuronal Interact.* 2018, 60, 123–128. [CrossRef]

96. Bellavia, D.; Raimondi, L.; Costa, V.; De Luca, A.; Carina, V.; Maglio, M.; Fini, M.; Alessandro, R.; Giavaresi, G. Engineered exosomes: A new promise for the management of musculoskeletal diseases. *Biochim. Biophys. Acta-Gen. Subj.* 2018, 1862, 1893–1901. [CrossRef]

97. Hiemer, B.; Krogull, M.; Bender, T.; Ziebart, J.; Krueger, S.; Bader, T.; Jonitz-Heincke, A. Ectopic Expression of CRISPR-CAS Genome Editing. *Stem Cells Transl. Med.* 2019, 8, 1–2. [CrossRef] [PubMed]

98. Lo Monaco, M.; Merckx, G.; Ratajczak, J.; Gervois, P.; Hilkens, P.; Clegg, P.; Bronckaers, A.; Vandeweerd, J.M.; Lambrichts, I. Stem Cells for Cartilage Repair: Preclinical Studies and Insights in Translational Animal Models and Outcome Measures. *Stem Cells Transl. Med.* 2018, 2018. [CrossRef]

99. De Bari, C.; Roelofs, A.J. Stem cell-based therapeutic strategies for cartilage defects and osteoarthritis. *Curr. Opin. Pharmacol.* 2018, 40, 74–80. [CrossRef]

100. Fernandes, T.L.; Kimura, H.A.; Pinheiro, C.C.G.; Shimomura, K.; Nakamura, N.; Ferreira, J.R.; Gomoll, A.H.; Hernandez, A.J.; Bueno, D.F. Human synovial mesenchymal stem cells good manufacturing practices for articular cartilage regeneration. *Tissue Eng.-Part C Methods* 2018, 24, 709–716. [CrossRef]

101. Cosenza, S.; Ruiz, M.; Toupet, K.; Jorgensen, C.; Noël, D. Mesenchymal stem cells derived exosomes and microparticles protect cartilage and bone from degradation in osteoarthritis. *Sci. Rep.* 2017, 7, 1–2. [CrossRef] [PubMed]

102. Cosenza, S.; Ruiz, M.; Toupet, K.; Bony, C.; Jorgensen, C.; Noël, D. Mesenchymal stem cells produced exosomes and microparticles that exert a similar chondroprotective effect in osteoarthritis. *Osteoarthr. Cartil.* 2018, 26, S297. [CrossRef] [PubMed]

103. Farhang, N.; Brunger, J.M.; Stover, J.D.; Thakore, P.I.; Lawrence, B.; Guilk, F.; Gersbach, C.A.; Setton, L.A.; Bowles, R.D. CRISPR-Based Epigenome Editing of Cytokine Receptors for the Promotion of Cell Survival and Tissue Deposition in Inflammatory Environments. *Tissue Eng. Part A* 2017, 23, 738–749. [CrossRef] [PubMed]

104. Matsukawa, A.; Yoshinaga, M. Sequential generation of cytokines during the initiative phase of inflammation, with reference to neutrophils. *Inflammation Res.* 1998, 47 (Suppl. 3), S137–S144. [CrossRef]

105. Cigan, A.D.; Roach, B.L.; Nims, R.J.; Tan, A.R.; Albro, M.B.; Stoker, A.M.; Cook, J.L.; Vinjak-Novakovic, G.; Hung, C.T.; Ateshian, G.A. High seeding density of human chondrocytes in agarose produces tissue-engineered cartilage approaching native mechanical and biochemical properties. *J. Biomech.* 2016, 49, 1909–1917. [CrossRef]

106. Karlson, T.A.; Pernas, P.F.; Staerk, J.; Caglayan, S.; Brinchmann, J.E. Generation of IL1β-resistant chondrocytes using CRISPR-CAS genome editing. *Osteoarthr. Cartil.* 2016, 24, S325. [CrossRef]
107. Lambert, L.J.; Challa, A.K.; Niu, A.; Zhou, L.; Tucholski, J.; Johnson, M.S.; Nagy, T.R.; Eberhardt, A.W.; Estep, P.N.; Kesterson, R.A.; et al. Increased trabecular bone and improved biomechanics in an osteocalcin-null rat model created by CRISPR/Cas9 technology. DMM Dis. Model. Mech. 2016, 9, 1169–1179. [CrossRef]

108. Asahara, H. Current Status and Strategy of microRNA Research for Cartilage Development and Osteoarthritis Pathogenesis. J. Bone Metab. 2016, 23, 121–127. [CrossRef]

109. Huang, Y.; Askew, E.B.; Knudson, C.B.; Knudson, W. CRISPR/Cas9 knockout of HAS2 in rat chondrosarcoma chondrocytes demonstrates the requirement of hyaluronan for aggrecan retention. Matrix Biol. 2016, 56, 74–94. [CrossRef]

110. Brunger, J.M.; Zutshi, A.; Willard, V.P.; Gersbach, C.A.; Guilak, F. Genome Engineering of Stem Cells for Autonomously Regulated, Closed-Loop Delivery of Biologic Drugs. Stem Cell Rep. 2017, 8, 1202–1213. [CrossRef]

111. Khakshooy, A.; Balenton, N.; Chiappelli, F. Lubricin: A Principal Modulator of the Psychoneuroendocrine-Osteoimmune Interactome-Implications for Novel Treatments of Osteoarthritic Pathologies. Bioinformation 2017, 13, 343–346. [CrossRef] [PubMed]

112. Rice, S.J.; Aubourg, G.; Sorial, A.K.; Almarza, D.; Tselepi, M.; Deehan, D.J.; Reynard, L.N.; Loughlin, J. Identification of a novel, methylation-dependent, RUNX2 regulatory region associated with osteoarthritis risk. Hum. Mol. Genet. 2018, 27, 3464–3474. [CrossRef] [PubMed]

113. Ye, Y.; Baek, S.-H.; Ye, Y.; Zhang, T. Proteomic characterization of endogenous substrates of mammalian ubiquitin ligase Hrd1. Cell Biosci. 2018, 8, 46. [CrossRef] [PubMed]

114. Seidl, C.I.; Fulga, T.A.; Murphy, C.L. CRISPR-Cas9 targeting of MMP13 in human chondrocytes leads to significantly reduced levels of the metalloproteinase and enhanced type II collagen accumulation. Osteoarthr. Cartil. 2019, 27, 140–147. [CrossRef]

115. Varela-Eiríñ, M.; Varela-Vázquez, A.; Guitián-Camaño, A.; Paino, C.L.; Mato, V.; Largo, R.; Aasen, T.; Tabernero, A.; Fonseca, E.; Kandouz, M.; et al. Targeting of chondrocyte plasticity via connexin43 modulation attenuates cellular senescence and fosters a pro-regenerative environment in osteoarthritis. Cell Death Dis. 2018, 9, 1–6. [CrossRef] [PubMed]

116. Ren, X.; Hu, B.; Song, M.; Ding, Z.; Dang, Y.; Liu, Z.; Zhang, W.; Ji, Q.; Ren, R.; Ding, J.; et al. Maintenance of Nucleolar Homeostasis by CBX4 Alleviates Senescence and Osteoarthritis. Cell Rep. 2019, 26, 3643–3656. [CrossRef] [PubMed]

117. Fu, L.; Hu, Y.; Song, M.; Liu, Z.; Zhang, W.; Yu, F.X.; Wu, J.; Wang, S.; Belmonte, J.C.I.; Chan, P.; et al. Up-regulation of FOXD1 by yap alleviates senescence and osteoarthritis. PLoS Biol. 2019, 17, e3000201. [CrossRef]

118. Nishimasu, H.; Shi, X.; Ishiguro, S.; Gao, L.; Hirano, S.; Okazaki, S.; Noda, T.; Abudayyeh, O.O.; Gootenberg, J.S.; Mori, H.; et al. Engineered CRISPR-Cas9 nuclease with expanded targeting space. Science 2018, 361, 1259–1262. [CrossRef]

119. O’Brien, J.; Hayder, H.; Zayed, Y.; Peng, C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front. Endocrinol. 2018, 9, 402. [CrossRef]

120. Ramos, Y.F.M.; Meulenbelt, I. The role of epigenetics in osteoarthritis: Current perspective. Curr. Opin. Rheumatol. 2017, 29, 119–129. [CrossRef]